BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Home > article

Health watchdog revokes license for cell-mediated gene therapy for degenerative arthritis

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : May 28, 2019, 12:32 | Updated : May 28, 2019, 16:56
  • 트위터
  • 페이스북
  • 웨이보

[Aju Business Daily DB]


SEOUL -- South Korea's state public health watchdog revoked the license for Invossa, the world's first cell-mediated gene therapy for degenerative arthritis, for concealing a research mistake that led the manufacturer to mislabel an ingredient.

The Ministry of Food and Drug Safety said Tuesday that Invossa's key ingredient was identified as kidney cells, not cartilage cells as listed in documents submitted at the time of authorization. Data submitted by Kolon Life Science was found to be false, it said, urging prosecutors to launch a criminal probe into the biotech arm of South Korea's Kolon Group.

The ministry accused Kolon Life Science of submitting false data and hiding major facts identified before approval in July 2017. Korea Exchange suspended trading of Kolon Life Science and its U.S. subsidiary, Kolon TissueGene, to protect investors.

Kolon Life Science is suspected of knowing about the mistake before submitting an application, but the company argued that there was no cover-up. "The data submitted was not complete because we didn't have enough data on the initial development phase as of now, but there was no fabrication or cover-up," Kolon Life Science said in a statement.

Sales and distribution of Invossa were suspended on March 31 after Kolon TissueGene found during U.S. clinical trials that a key ingredient was different from that described in the data submitted at the time of permission in South Korea. Kolon Life Science apologized for having used a wrong name, saying that there has been no change in the constituents of Invossa, which used the combination of human chondrocytes and transfected cells with TGF-β1 genes.

Kolon TissueGene found in March 2017 that the substance of the drug had changed through a consignment producer and notified Kolon Life Science. On April 1, Kolon TissueGene suspended patient recruitment for phase 3 clinical trials involving patients diagnosed with knee osteoarthritis at 60 American hospitals.

Invossa has been administered to more than 3,500 people for 11 years at home, but Kolong Life officials claimed to have discovered no serious side effects. The drug is not covered by health insurance with its single injection cost standing at about seven million won ($5,900).

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Kolons biosimilar company suspends U.S. clinical trials for Invossa.
    Kolon's biosimilar company suspends U.S. clinical trials for…
  • .Prosecutors raid  Kolon Life Sciences offices to secure cover-up evidence.
    Prosecutors raid Kolon Life Science's offices to secure cov…
  • .Kolon claims its arthritis gene therapy medicine is effective for 36 months.
    Kolon claims its arthritis gene therapy medicine is effectiv…
  • .Kolon exports worlds first arthritis gene therapy tech for $438 mil.
    Kolon exports world's first arthritis gene therapy tech for …
  • .TissueGenes osteoarthritis therapy allowed to conduct U.S. clinical trials.
    TissueGene's osteoarthritis therapy allowed to conduct U.S. …

Real Time Photo News

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

  • .[FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene.

    [FOCUS] BTS agency leagues with Universal Music to launch new K-pop band in US music scene

  • .CJ ENM aims to become major visual content producer thru partnership with Epic Games .

    CJ ENM aims to become major visual content producer thru partnership with Epic Games

  • .​Solo singer Sunmi to come back with new album Tail.

    ​Solo singer Sunmi to come back with new album 'Tail'

  • .Big Hits live-streaming joint venture gains reinforcements from Universal Music, YG.

    Big Hit's live-streaming joint venture gains reinforcements from Universal Music, YG

Latest News

more+

  • Prime Minister Chung stresses importance of 'borderless communication channel' to minimize informati…
  • State hospital succeeds in inserting wireless pacemakers into hearts of bradyarrhythmia patients
  • LG Electronics' joint venture with Canada's Magna awaits approval by shareholders in March
  • Sajo Seafood to launch raw tuna menu delivery service
  • Researchers find new roundworm species near Dokdo
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view